PsychonautWiki Archive

LAE-32: Difference between revisions

← Older edit
>Tracer
>Dextromethorphan
added substancebox
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{SubstanceBox
{{approval}}
 
{{stub}}
    <!-- Special Parameters -->
{{SummarySheet}}
    |displayClasses={{{displayClasses|}}}
{{SubstanceBox/LAE-32}}
    |MaterialTable_MaxWidth=250px
    |MaterialTable_Title={{PAGENAME}}
 
    <!-- Modules -->
    |ModuleSource=false
    |ModuleCombination=false
    |ModuleStructure=true
    |ModuleNomenclature=true
    |ModuleClassMembership=true
    |ModuleROA=true
 
    <!-- Source -->
    |PhotoImageFile=
    |PhotoImageWidth=
    |PhotoImageCaption=


    <!-- Combination -->
'''Lysergic acid ethylamide''' (also known as '''LAE-32''', '''LAE''', and '''d-ethyllysergamide''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. It is one of the least known and least researched psychedelic substances.
    |CombinationImage1_Caption=
    |CombinationImage1_File=
    |CombinationImage1_Width=


    |CombinationImage2_Caption=
    |CombinationImage2_File=
    |CombinationImage2_Width=
    |CombinationImage3_Caption=
    |CombinationImage3_File=
    |CombinationImage3_Width=
    <!-- Structure -->
    |MolecularStructureCaption=Molecular structure of Lysergic Acid Ethylamide
    |SkeletalImageFile=File:LAE-32.svg
    |SkeletalImageWidth=245px
    |3DImageFile=
    |3DImageWidth=
    <!-- Nomenclature -->
    |NameCommon=LAE-32, LAE
    |NameSubstitution=d-Lysergic acid ethylamide
    |NameSystematic=N-ethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
    <!-- Class Membership -->
    |EffectClass=[[psychoactive class::Psychedelic]]
    |ChemicalClass=[[chemical class::Lysergamide]]
    <!-- Dosage/Duration per ROA -->
    |OralROA=false
    |OralROA_Collapsed=true
    |OralROA_Caption=
    |OralROA_Bioavailability=
    |OralROA_Threshold=
    |OralROA_Light=
    |OralROA_Common=
    |OralROA_Strong=
    |OralROA_Heavy=
    |OralROA_TimelineFile=
    |OralROA_TimelineWidth=
    |OralROA_Duration=
    |OralROA_Onset=
    |OralROA_Comeup=
    |OralROA_Peak=
    |OralROA_Offset=
    |OralROA_Aftereffects=
    |SublingualROA=true
    |SublingualROA_Collapsed=false
    |SublingualROA_Caption=
    |SublingualROA_Bioavailability=
    |SublingualROA_Microdose=
    |SublingualROA_Threshold=[[Sublingual threshold dose::0.5-1.5]] [[Sublingual dose units::mg]]
    |SublingualROA_Light=
    |SublingualROA_Common=
    |SublingualROA_Strong=
    |SublingualROA_Heavy=
    |SublingualROA_TimelineFile=
    |SublingualROA_TimelineWidth=
    |SublingualROA_Duration=
    |SublingualROA_Onset=
    |SublingualROA_Comeup=
    |SublingualROA_Peak=
    |SublingualROA_Offset=
    |SublingualROA_Aftereffects=
    |BuccalROA=false
    |BuccalROA_Collapsed=true
    |BuccalROA_Caption=Presumes no tolerance
    |BuccalROA_Bioavailability=
    |BuccalROA_Threshold=< x mg
    |BuccalROA_Light=x - x mg
    |BuccalROA_Common=x - x mg
    |BuccalROA_Strong=x - x mg
    |BuccalROA_Heavy= >  mg
    |BuccalROA_TimelineFile=
    |BuccalROA_TimelineWidth=
    |BuccalROA_Duration=x - x hours
    |BuccalROA_Onset=x minutes
    |BuccalROA_Peak=x hours
    |BuccalROA_Offset=x hours
    |BuccalROA_Aftereffects=x hours
    |InsufflatedROA=false
    |InsufflatedROA_Collapsed=true
    |InsufflatedROA_Caption=
    |InsufflatedROA_Bioavailability=
    |InsufflatedROA_Threshold=< x mg
    |InsufflatedROA_Light=x - x mg
    |InsufflatedROA_Common=x - x mg
    |InsufflatedROA_Strong=x - x mg
    |InsufflatedROA_Heavy= >  mg
    |InsufflatedROA_TimelineFile=
    |InsufflatedROA_TimelineWidth=
    |InsufflatedROA_Duration=x - x hours
    |InsufflatedROA_Onset=x minutes
    |InsufflatedROA_Peak=x hours
    |InsufflatedROA_Offset=x hours
    |InsufflatedROA_Aftereffects=x hours
    |RectalROA=false
    |RectalROA_Collapsed=true
    |RectalROA_Caption=Presumes no tolerance
    |RectalROA_Bioavailability=
    |RectalROA_Threshold=< x mg
    |RectalROA_Light=x - x mg
    |RectalROA_Common=x - x mg
    |RectalROA_Strong=x - x mg
    |RectalROA_Heavy= >  mg
    |RectalROA_TimelineFile=
    |RectalROA_TimelineWidth=
    |RectalROA_Duration=x - x hours
    |RectalROA_Onset=x minutes
    |RectalROA_Peak=x hours
    |RectalROA_Offset=x hours
    |RectalROA_Aftereffects=x hours
    |TransdermalROA=false
    |TransdermalROA_Collapsed=true
    |TransdermalROA_Caption=Presumes no tolerance
    |TransdermalROA_Bioavailability=
    |TransdermalROA_Threshold=< x mg
    |TransdermalROA_Light=x - x mg
    |TransdermalROA_Common=x - x mg
    |TransdermalROA_Strong=x - x mg
    |TransdermalROA_Heavy= >  mg
    |TransdermalROA_TimelineFile=
    |TransdermalROA_TimelineWidth=
    |TransdermalROA_Duration=x - x hours
    |TransdermalROA_Onset=x minutes
    |TransdermalROA_Peak=x hours
    |TransdermalROA_Offset=x hours
    |TransdermalROA_Aftereffects=x hours
    |SubcutaneousROA=false
    |SubcutaneousROA_Collapsed=true
    |SubcutaneousROA_Caption=Presumes no tolerance
    |SubcutaneousROA_Bioavailability=
    |SubcutaneousROA_Threshold=< x mg
    |SubcutaneousROA_Light=x - x mg
    |SubcutaneousROA_Common=x - x mg
    |SubcutaneousROA_Strong=x - x mg
    |SubcutaneousROA_Heavy= >  mg
    |SubcutaneousROA_TimelineFile=
    |SubcutaneousROA_TimelineWidth=
    |SubcutaneousROA_Duration=x - x hours
    |SubcutaneousROA_Onset=x minutes
    |SubcutaneousROA_Peak=x hours
    |SubcutaneousROA_Offset=x hours
    |SubcutaneousROA_Aftereffects=x hours
    |IntramuscularROA=false
    |IntramuscularROA_Collapsed=true
    |IntramuscularROA_Caption=Presumes no tolerance
    |IntramuscularROA_Bioavailability=
    |IntramuscularROA_Threshold=< x mg
    |IntramuscularROA_Light=x - x mg
    |IntramuscularROA_Common=x - x mg
    |IntramuscularROA_Strong=x - x mg
    |IntramuscularROA_Heavy= >  mg
    |IntramuscularROA_TimelineFile=
    |IntramuscularROA_TimelineWidth=
    |IntramuscularROA_Duration=x - x hours
    |IntramuscularROA_Onset=x minutes
    |IntramuscularROA_Peak=x hours
    |IntramuscularROA_Offset=x hours
    |IntramuscularROA_Aftereffects=x hours
    |IntravenousROA=false
    |IntravenousROA_Collapsed=true
    |IntravenousROA_Caption=Presumes no tolerance
    |IntravenousROA_Bioavailability=
    |IntravenousROA_Threshold=< x mg
    |IntravenousROA_Light=x - x mg
    |IntravenousROA_Common=x - x mg
    |IntravenousROA_Strong=x - x mg
    |IntravenousROA_Heavy= >  mg
    |IntravenousROA_TimelineFile=
    |IntravenousROA_TimelineWidth=
    |IntravenousROA_Duration=x - x hours
    |IntravenousROA_Onset=x minutes
    |IntravenousROA_Peak=x hours
    |IntravenousROA_Offset=x hours
    |IntravenousROA_Aftereffects=x hours
}}
{{SummarySheet}}
'''Lysergic acid ethylamide''' (also known as '''LAE-32''', '''LAE''', and '''d-ethyllysergamide''') is a semisynthetic [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class that is structurally similar to LSD.
LAE-32 is one of the least known and least researched psychedelic substances.
The pharmacology of LAE-32 is complex{{citation needed}}, but it acts primarily by binding to [[serotonin]] [[receptors]] in the brain, much like LSD and other serotonergic psychedelics.{{citation needed}}
The pharmacology of LAE-32 is complex{{citation needed}}, but it acts primarily by binding to [[serotonin]] [[receptors]] in the brain, much like LSD and other serotonergic psychedelics.{{citation needed}}


==The CIA and Project MKULTRA Findings==
==History and culture==
{{historyStub}}
===The CIA and Project MKULTRA Findings===
LAE-32 was experimented with by the CIA as part of Project MKULTRA. It was reported to create a condition similar to that of schizophrenia in mentally healthy individuals, characterized by indifference and depersonalization. While it was reported that, when used on schizophrenics, it created a condition that allowed the patients to become indifferent to their hallucinations and cease hallucinatory excitation.
LAE-32 was experimented with by the CIA as part of Project MKULTRA. It was reported to create a condition similar to that of schizophrenia in mentally healthy individuals, characterized by indifference and depersonalization. While it was reported that, when used on schizophrenics, it created a condition that allowed the patients to become indifferent to their hallucinations and cease hallucinatory excitation.


==Chemistry==
==Chemistry==
LAE-32, or d-lysergic acid ethylamide, is a semisynthetic substance of the [[lysergamide]] family. LAE-32's chemical structure consists of a bicyclic hexahydroindole ring fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline an N, generally N-ethyl carboxamide is bound, LAE-32 is additionally substituted at carbon 6 with a methyl group.
LAE-32, or d-lysergic acid ethylamide, is a semisynthetic substance of the [[lysergamide]] family.  
 
Its chemical structure consists of a bicyclic hexahydroindole ring fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline an N, generally N-ethyl carboxamide is bound, LAE-32 is additionally substituted at carbon 6 with a methyl group.


==Pharmacology==
==Pharmacology==
Retrieved from "https://psy.st/wiki/LAE-32"